subscribeSubscribe
TAGRISSO demonstrated efficacy benefit in EGFR-mutated lung cancer

TAGRISSO demonstrated efficacy benefit in EGFR-mutated lung cancer
BUSINESSWIRE
20 Feb 2024
Share Share
U.S. FDA approves AstraZeneca`s Tagrisso-chemo combo

U.S. FDA approves AstraZeneca`s Tagrisso-chemo combo
PRESS RELEASE
17 Feb 2024
Share Share
Kairos Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105

Kairos Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105
GLOBENEWSWIRE
16 Jan 2024
Share Share
AstraZeneca picks up a friend for Tagrisso in $40M upfront deal

AstraZeneca picks up a friend for Tagrisso in $40M upfront deal
Annalee Armstrong FIERCE BIOTECH
02 Jan 2024
Share Share
TAGRISSO reduced the risk of disease progression in the brain by 42%

TAGRISSO reduced the risk of disease progression in the brain by 42%
BUSINESSWIRE
21 Oct 2023
Share Share
ESMO: Should AZ worry about J&J`s Tagrisso head-to-head win?

ESMO: Should AZ worry about J&J`s Tagrisso head-to-head win?
Angus Liu FIERCE PHARMA
17 Oct 2023
Share Share
AstraZeneca’s Tagrisso, chemotherapy combo granted speedy FDA review

AstraZeneca’s Tagrisso, chemotherapy combo granted speedy FDA review
PRESS RELEASE
17 Oct 2023
Share Share
J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win
Lei Lei Wu ENDPTS
29 Sep 2023
Share Share
AZ`s Tagrisso combo shows edge, but survival data leave doubts

AZ`s Tagrisso combo shows edge, but survival data leave doubts
BUSINESSWIRE
12 Sep 2023
Share Share
Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemotherapy Alone in Patients with EGFR-Mutated Non-Small Cell Lung Cancer after Disease Progression on Osimertinib

Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemotherapy Alone in Patients with EGFR-Mutated Non-Small Cell Lung Cancer after Disease Progression on Osimertinib
PR NEWSWIRE
06 Sep 2023
Share Share